Litcius/Paper detail

RNA polymerase mutations cause cephalosporin resistance in clinical Neisseria gonorrhoeae isolates

Samantha G. Palace, Yi Wang, Daniel H. F. Rubin, Michael A. Welsh, Tatum D. Mortimer, Kevin Cole, David W. Eyre, Suzanne Walker, Yonatan H. Grad

2020eLife50 citationsDOIOpen Access PDF

Abstract

Increasing Neisseria gonorrhoeae resistance to ceftriaxone, the last antibiotic recommended for empiric gonorrhea treatment, poses an urgent public health threat. However, the genetic basis of reduced susceptibility to ceftriaxone is not completely understood: while most ceftriaxone resistance in clinical isolates is caused by target site mutations in penA, some isolates lack these mutations. We show that penA-independent ceftriaxone resistance has evolved multiple times through distinct mutations in rpoB and rpoD. We identify five mutations in these genes that each increase resistance to ceftriaxone, including one mutation that arose independently in two lineages, and show that clinical isolates from multiple lineages are a single nucleotide change from ceftriaxone resistance. These RNA polymerase mutations cause large-scale transcriptional changes without altering susceptibility to other antibiotics, reducing growth rate, or deranging cell morphology. These results underscore the unexpected diversity of pathways to resistance and the importance of continued surveillance for novel resistance mutations.

Topics & Concepts

rpoBNeisseria gonorrhoeaeCeftriaxoneBiologyAntibiotic resistanceGeneticsCephalosporinMicrobiologyMutationDrug resistanceGeneGonorrheaAntibioticsVirology16S ribosomal RNAHuman immunodeficiency virus (HIV)Reproductive tract infections researchBacterial Infections and VaccinesSyphilis Diagnosis and Treatment